 | Up a level |
Dal Pra, A; Ghadjar, P; Hayoz, S; Liu, V Y T; Spratt, D E; Thompson, D J S; Davicioni, E; Huang, H-C; Zhao, X; Liu, Y; Schär, C; Gut, P; Plasswilm, L; Hölscher, T; Polat, B; Hildebrandt, G; Müller, A-C; Pollack, A; Thalmann, G N; Zwahlen, D; ... (2022). Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy - An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial. Annals of oncology, 33(9), pp. 950-958. Elsevier 10.1016/j.annonc.2022.05.007
Metzger, T; Thalmann, G N; Zehnder, P (2012). [Lymphadenectomy for bladder cancer: current status and controversies]. Urologe, 51(3), pp. 310-8. Berlin: Springer-Verlag 10.1007/s00120-012-2833-6
Moltzahn, F; Thalmann, G N (2012). [Bone metastasis in prostate cancer]. Urologe, 51(1), pp. 20-6. Berlin: Springer-Verlag 10.1007/s00120-011-2741-1
Kitz, M; Preisser, S; Wetterwald, A; Jaeger, M; Thalmann, G N; Frenz, M (2011). Vapor bubble generation around gold nano-particles and its application to damaging of cells. Biomedical optics express, 2(2), pp. 291-304. Washington, D.C.: Optical Society of America 10.1364/BOE.2.000291
Burkhard, F C; Thalmann, G N; Studer, U E; Schumacher, M; Danuser, H J; Zingg, E J (2010). [Studer ileum neobladder]. Aktuelle Urologie, 41(1), pp. 67-77. Stuttgart: Thieme 10.1055/s-0029-1233501
Fleischmann, A; Schobinger, S; Markwalder, R; Schumacher, M; Burkhard, F; Thalmann, G N; Studer, U E (2008). Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival. Histopathology, 53(4), pp. 468-75. Oxford: Blackwell Scientific Publications 10.1111/j.1365-2559.2008.03129.x
Müller, R M; Thalmann, G N; Studer, U E (2006). [Old and new interventional therapies in the treatment of symptomatic benign prostate hyperplasia (BPH)]. Therapeutische Umschau, 63(2), pp. 129-34. Bern: Huber
Schumacher, M; Thalmann, G N; Studer, U E (2006). [Radical prostatectomy in the treatment of organ confined prostate cancer]. Therapeutische Umschau, 63(2), pp. 143-50. Bern: Huber
